PSYCH Symposium returned at the British Museum on 6 July to explore how psychedelic medicines can innovate healthcare – from mental health to eating disorders and...
PSYCH Symposium: London 2023 brought together key stakeholders to explore the landscape of psychedelic medicine at the British Museum on Thursday, 6 July.
Psychedelic Medicine Investment Fund Negev Capital is aiming to innovate mental healthcare in Europe by providing funding to companies on the cutting edge of psychedelic research.
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of experts will discuss how psychedelics could innovate eating disorder care.
Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
For the first time, the U.S.
Psychedelics stand at a pivotal crossroads in mental health, offering the prospect of novel therapeutic avenues to address multiple mental conditions, from treatment-resistant depression to post-traumatic...
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of changemakers and MEPs will discuss the future of psychedelic healthcare in...
Alexander Shulgin, best known for introducing MDMA to the psychological community, also created over 230 novel psychoactive compounds and documented their effects in the book PiHKAL:...
